DrugDashboards

Cisatracurium Besylate

Cisatracurium Besylate · CISATRACURIUM BESYLATE 10 mg/mL · Injection, Solution · Intravenous · Hospira, Inc.

NDC 00409-1103-01 · 10 VIAL, SINGLE-DOSE in 1 CARTON / 20 mL in 1 VIAL, SINGLE-DOSE · ANDA · View full market →

The short version

4 companies supply this market — a reasonable cushion if one runs into trouble.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$2,732.05
Reported to Texas DSHS · 2026 annual filing · Pfizer Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Where it's made

  • Hospira, Inc.United States
    analysis · label · manufacture · pack

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA203236
TE code
AP
Approval date
Mar 30, 2018
Patents / exclusivity
None on file

Shortage history

  • Planned discontinuation — Cisatracurium Besylate, Injection, 20 mg/10 mL (2 mg/mL) Multidose Vial (NDC 0409-1208-01)May 6, 2026
  • Planned discontinuation — Cisatracurium Besylate, Injection, 200 mg/20ml (10 mg/mL) Single Dose Vial (NDC 0409-1103-01)May 6, 2026

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Cisatracurium Besylate (Injection, Solution)

LabelerStrengthFirst seenLast seen
Fresenius Kabi USA, LLCCISATRACURIUM BESYLATE 2 mg/mLJul 15, 2026Sep 3, 2026
Hospira, Inc.CISATRACURIUM BESYLATE 2 mg/mLJul 15, 2026Sep 3, 2026
Meitheal Pharmaceuticals Inc.CISATRACURIUM BESYLATE 20 mg/10mLJul 15, 2026Sep 3, 2026
Fresenius Kabi USA, LLCCISATRACURIUM BESYLATE 10 mg/mLJul 15, 2026Sep 2, 2026
Hospira, Inc.CISATRACURIUM BESYLATE 10 mg/mLJul 15, 2026Sep 2, 2026
Avenacy, LLCCISATRACURIUM BESYLATE 10 mg/mLAug 18, 2026Sep 1, 2026
Meitheal Pharmaceuticals Inc.CISATRACURIUM BESYLATE 200 mg/20mLJul 15, 2026Aug 31, 2026
Meitheal Pharmaceuticals Inc.CISATRACURIUM BESYLATE 10 mg/5mLJul 15, 2026Aug 31, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Cisatracurium Besylate — NDC 00409-1103-01," retrieved September 3, 2026, https://drugdashboards.com/drug/00409110301.

Free to cite with attribution — see how the data is put together.